Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors

B. Surendra Baliga, Betty Sue Pace, Hsueh Hua Chen, Arvind K. Shah, Yih Ming Yang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Hydroxyurea (HU) is a widely used cytotoxic agent that is known to induce fetal hemoglobin (HbF) production and is presently used to ameliorate the severity of pain episodes in patients with sickle cell anemia (HbSS). Previously we have shown that HU inhibits growth of burst forming unit-erythroid (BFU-E) colonies in a dose-dependent manner, while fetal hemoglobin levels were increased. In the present report, we extended our analysis demonstrating the number of S phase cells is significantly higher for HbSS patients that respond to HU therapy. Studies were completed in vitro using erythroid progenitors derived from umbilical cord samples or peripheral blood from patients with HbS-hereditary persistence of fetal hemoglobin (HbS-HPFH) or HbSS disease. The effect of HU on (a) S phase erythroid progenitors, (b) BFU-E colony growth, (c) HbF levels in BFU-E colonies, and (d) total cellular RNA synthesis was analyzed in vitro for the three groups. The level of S phase erythroid progenitors was similar for all three groups and BFU-E colony growth was inhibited 92-94% for all samples in a dose-dependent manner. The HbF levels were increased in BFU-E colonies from HbSS patients (control, 4.0% ± 1.15% vs. +HU, 22.67% ± 2.03%) whereas HbF levels were decreased in BFU-E colonies derived from umbilical cord samples (control, 80% ± 9.07% vs. +HU, 35.7% ± 4.81%) or HbS-HPFH patients (control, 49.87% ± 3.84% vs. +HU, 23.3% ± 0.88%). Total RNA synthesis measured by 3H-uridine incorporation increased with increasing concentrations of HU; however, actinomycin D inhibited HU-induced RNA synthesis. These results suggest that HU can inhibit an active globin gene without preference and that newly synthesized RNA is under transcriptional control mechanisms. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)227-233
Number of pages7
JournalAmerican Journal of Hematology
Volume65
Issue number3
DOIs
StatePublished - Oct 30 2000

Fingerprint

Fetal Hemoglobin
Erythroid Precursor Cells
Hydroxyurea
S Phase
RNA
Umbilical Cord
Growth
Globins
Uridine
Cytotoxins
Sickle Cell Anemia
Dactinomycin
Pain

Keywords

  • BFU-E
  • Hb F
  • Hydroxyurea
  • Sickle cell anemia

ASJC Scopus subject areas

  • Hematology

Cite this

Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. / Surendra Baliga, B.; Pace, Betty Sue; Chen, Hsueh Hua; Shah, Arvind K.; Yang, Yih Ming.

In: American Journal of Hematology, Vol. 65, No. 3, 30.10.2000, p. 227-233.

Research output: Contribution to journalArticle

Surendra Baliga, B. ; Pace, Betty Sue ; Chen, Hsueh Hua ; Shah, Arvind K. ; Yang, Yih Ming. / Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. In: American Journal of Hematology. 2000 ; Vol. 65, No. 3. pp. 227-233.
@article{7f1a38841a4c48d4b37d47f4aa273572,
title = "Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors",
abstract = "Hydroxyurea (HU) is a widely used cytotoxic agent that is known to induce fetal hemoglobin (HbF) production and is presently used to ameliorate the severity of pain episodes in patients with sickle cell anemia (HbSS). Previously we have shown that HU inhibits growth of burst forming unit-erythroid (BFU-E) colonies in a dose-dependent manner, while fetal hemoglobin levels were increased. In the present report, we extended our analysis demonstrating the number of S phase cells is significantly higher for HbSS patients that respond to HU therapy. Studies were completed in vitro using erythroid progenitors derived from umbilical cord samples or peripheral blood from patients with HbS-hereditary persistence of fetal hemoglobin (HbS-HPFH) or HbSS disease. The effect of HU on (a) S phase erythroid progenitors, (b) BFU-E colony growth, (c) HbF levels in BFU-E colonies, and (d) total cellular RNA synthesis was analyzed in vitro for the three groups. The level of S phase erythroid progenitors was similar for all three groups and BFU-E colony growth was inhibited 92-94{\%} for all samples in a dose-dependent manner. The HbF levels were increased in BFU-E colonies from HbSS patients (control, 4.0{\%} ± 1.15{\%} vs. +HU, 22.67{\%} ± 2.03{\%}) whereas HbF levels were decreased in BFU-E colonies derived from umbilical cord samples (control, 80{\%} ± 9.07{\%} vs. +HU, 35.7{\%} ± 4.81{\%}) or HbS-HPFH patients (control, 49.87{\%} ± 3.84{\%} vs. +HU, 23.3{\%} ± 0.88{\%}). Total RNA synthesis measured by 3H-uridine incorporation increased with increasing concentrations of HU; however, actinomycin D inhibited HU-induced RNA synthesis. These results suggest that HU can inhibit an active globin gene without preference and that newly synthesized RNA is under transcriptional control mechanisms. (C) 2000 Wiley-Liss, Inc.",
keywords = "BFU-E, Hb F, Hydroxyurea, Sickle cell anemia",
author = "{Surendra Baliga}, B. and Pace, {Betty Sue} and Chen, {Hsueh Hua} and Shah, {Arvind K.} and Yang, {Yih Ming}",
year = "2000",
month = "10",
day = "30",
doi = "10.1002/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V",
language = "English (US)",
volume = "65",
pages = "227--233",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors

AU - Surendra Baliga, B.

AU - Pace, Betty Sue

AU - Chen, Hsueh Hua

AU - Shah, Arvind K.

AU - Yang, Yih Ming

PY - 2000/10/30

Y1 - 2000/10/30

N2 - Hydroxyurea (HU) is a widely used cytotoxic agent that is known to induce fetal hemoglobin (HbF) production and is presently used to ameliorate the severity of pain episodes in patients with sickle cell anemia (HbSS). Previously we have shown that HU inhibits growth of burst forming unit-erythroid (BFU-E) colonies in a dose-dependent manner, while fetal hemoglobin levels were increased. In the present report, we extended our analysis demonstrating the number of S phase cells is significantly higher for HbSS patients that respond to HU therapy. Studies were completed in vitro using erythroid progenitors derived from umbilical cord samples or peripheral blood from patients with HbS-hereditary persistence of fetal hemoglobin (HbS-HPFH) or HbSS disease. The effect of HU on (a) S phase erythroid progenitors, (b) BFU-E colony growth, (c) HbF levels in BFU-E colonies, and (d) total cellular RNA synthesis was analyzed in vitro for the three groups. The level of S phase erythroid progenitors was similar for all three groups and BFU-E colony growth was inhibited 92-94% for all samples in a dose-dependent manner. The HbF levels were increased in BFU-E colonies from HbSS patients (control, 4.0% ± 1.15% vs. +HU, 22.67% ± 2.03%) whereas HbF levels were decreased in BFU-E colonies derived from umbilical cord samples (control, 80% ± 9.07% vs. +HU, 35.7% ± 4.81%) or HbS-HPFH patients (control, 49.87% ± 3.84% vs. +HU, 23.3% ± 0.88%). Total RNA synthesis measured by 3H-uridine incorporation increased with increasing concentrations of HU; however, actinomycin D inhibited HU-induced RNA synthesis. These results suggest that HU can inhibit an active globin gene without preference and that newly synthesized RNA is under transcriptional control mechanisms. (C) 2000 Wiley-Liss, Inc.

AB - Hydroxyurea (HU) is a widely used cytotoxic agent that is known to induce fetal hemoglobin (HbF) production and is presently used to ameliorate the severity of pain episodes in patients with sickle cell anemia (HbSS). Previously we have shown that HU inhibits growth of burst forming unit-erythroid (BFU-E) colonies in a dose-dependent manner, while fetal hemoglobin levels were increased. In the present report, we extended our analysis demonstrating the number of S phase cells is significantly higher for HbSS patients that respond to HU therapy. Studies were completed in vitro using erythroid progenitors derived from umbilical cord samples or peripheral blood from patients with HbS-hereditary persistence of fetal hemoglobin (HbS-HPFH) or HbSS disease. The effect of HU on (a) S phase erythroid progenitors, (b) BFU-E colony growth, (c) HbF levels in BFU-E colonies, and (d) total cellular RNA synthesis was analyzed in vitro for the three groups. The level of S phase erythroid progenitors was similar for all three groups and BFU-E colony growth was inhibited 92-94% for all samples in a dose-dependent manner. The HbF levels were increased in BFU-E colonies from HbSS patients (control, 4.0% ± 1.15% vs. +HU, 22.67% ± 2.03%) whereas HbF levels were decreased in BFU-E colonies derived from umbilical cord samples (control, 80% ± 9.07% vs. +HU, 35.7% ± 4.81%) or HbS-HPFH patients (control, 49.87% ± 3.84% vs. +HU, 23.3% ± 0.88%). Total RNA synthesis measured by 3H-uridine incorporation increased with increasing concentrations of HU; however, actinomycin D inhibited HU-induced RNA synthesis. These results suggest that HU can inhibit an active globin gene without preference and that newly synthesized RNA is under transcriptional control mechanisms. (C) 2000 Wiley-Liss, Inc.

KW - BFU-E

KW - Hb F

KW - Hydroxyurea

KW - Sickle cell anemia

UR - http://www.scopus.com/inward/record.url?scp=0033784055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033784055&partnerID=8YFLogxK

U2 - 10.1002/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V

DO - 10.1002/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V

M3 - Article

VL - 65

SP - 227

EP - 233

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -